Lb-469807-04 efficacy and safety of apixaban versus aspirin according to cha2ds2-vasc score in patients with subclinical atrial fibrillation in artesia

ARTESiA showed that apixaban, compared to aspirin, significantly reduced stroke or systemic embolism (SE) but increased major bleeding in patients with subclinical atrial fibrillation (SCAF). To better inform benefit-to-risk decision-making for the use of apixaban, we evaluated the benefits and hazards of apixaban according to baseline CHA2DS2-VASc score.

Source: Heart Rhythm - May 2, 2024 Category: Cardiology Authors: Jeffrey S. Healey, Christopher Granger, William F. McIntyre, Marco Alings, Daniel Wojdyla, Chinthanie Ramasundarahettige, Lena Rivard, Dan Atar, David H. Birnie, Giuseppe Boriani, Guy Amit, Peter Leong-Sit, Claus H. Rinne, Gabor Duray, Michael R. Gold, St Source Type: research